{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:19:06Z","timestamp":1780510746450,"version":"3.54.1"},"reference-count":94,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines & Immunotherapeutics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/21645515.2026.2658911","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:48:23Z","timestamp":1780508903000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Depemokimab: A twice yearly anti\u2013IL 5 biologic for chronic rhinosinusitis with nasal polyps (CRSwNP) \u2013 A narrative review"],"prefix":"10.1080","volume":"22","author":[{"given":"Marn Joon","family":"Park","sequence":"first","affiliation":[{"name":"Stanford University School of Medicine","place":["Stanford, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph K.","family":"Han","sequence":"additional","affiliation":[{"name":"Macon & Joan Brock Virginia Health Sciences, Eastern Virginia Medical School of Old Dominion University","place":["Norfolk, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent K.","family":"Lam","sequence":"additional","affiliation":[{"name":"Macon & Joan Brock Virginia Health Sciences, Eastern Virginia Medical School of Old Dominion University","place":["Norfolk, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"issue":"29","key":"e_1_3_4_2_1","first-page":"1","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens WJ","year":"2020","unstructured":"Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, Toppila-Salmi S, Bernal-Sprekelsen M, Mullol J, Alobid I, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl S29):1\u201318.","journal-title":"Rhinology"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13875"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.12.1324"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S290424"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.09.063"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22369"},{"issue":"4","key":"e_1_3_4_8_1","first-page":"Cd011993","article-title":"Different types of intranasal steroids for chronic rhinosinusitis","volume":"4","author":"Chong LY","year":"2016","unstructured":"Chong LY, Head K, Hopkins C, Philpott C, Burton MJ, Schilder AG. Different types of intranasal steroids for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016;4(4):Cd011993.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22741"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin22.489"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31881-1"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.05.032"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00097-7"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.01.020"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22864"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.18787\/jr.2023.00029"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.18787\/jr.2023.00061"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.07.017"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12060951"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.28648"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-023-00823-1"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A1391"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.21053\/ceo.2024.00233"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.9.5171"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15002"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin22.903"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100674"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00197-7"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.12.978"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-025-00777-6"},{"issue":"1","key":"e_1_3_4_33_1","first-page":"42","article-title":"Depemokimab in eosinophilic asthma\u2013a new era in biological therapy?","volume":"31","author":"Pillay S","year":"2025","unstructured":"Pillay S. Depemokimab in eosinophilic asthma\u2013a new era in biological therapy? Afr J Thorac Crit Care Med. 2025;31(1):42.","journal-title":"Afr J Thorac Crit Care Med"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2406673"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.07.026"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S226575"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.798"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02037-0"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00049"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.16303"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.04.004"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13380"},{"key":"e_1_3_4_43_1","unstructured":"Dall\u2019Acqua WF Wu H Kiener P inventors; MedImmune LLC assignee. Molecules with extended half-lives compositions and uses thereof. US7658921B2. 2010 Feb 9."},{"key":"e_1_3_4_44_1","volume-title":"Medical (clinical) review: BLA 125526 (Nucala [mepolizumab])","author":"Food US, Drug Administration CfDE, Research","year":"2015","unstructured":"Food US, Drug Administration CfDE, Research. Medical (clinical) review: BLA 125526 (Nucala [mepolizumab]). Silver Spring (MD): U.S. Food and Drug Administration; 2015."},{"key":"e_1_3_4_45_1","unstructured":"GlaxoSmithKline Intellectual Property Development Ltd. inventor; World Intellectual Property Organization assignee. Biopharmaceutical compositions and related methods. US20180340023A1. 2018 Nov 29."},{"key":"e_1_3_4_46_1","unstructured":"Grant S Orecchia M Akinseye C Hook L Lewis A Bhinder T inventors; GlaxoSmithKline Intellectual Property Development Ltd. assignee. Biopharmaceutical compositions and related methods. SG10201913497XA. 2020 Sep 29."},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1207641"},{"key":"e_1_3_4_48_1","first-page":"1","article-title":"Metabolism of immunoglobulins","volume":"13","author":"Waldmann TA","year":"1969","unstructured":"Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy. 1969;13:1\u2013110.","journal-title":"Prog Allergy"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2015.02.007"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-017-0408-4"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01540"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.119.086488"},{"issue":"68","key":"e_1_3_4_54_1","first-page":"OA3644","article-title":"Enhanced in vitro potency of depemokimab for interleukin-5 inhibition versus mepolizumab","volume":"64","author":"Jackson D","year":"2024","unstructured":"Jackson D, Bahra P, Affleck K, Zangrilli J, Howarth P, Finney-Hayward T, Singh D. Enhanced in vitro potency of depemokimab for interleukin-5 inhibition versus mepolizumab. Eur Respir J. 2024;64(suppl 68):OA3644.","journal-title":"Eur Respir J"},{"issue":"68","key":"e_1_3_4_55_1","first-page":"OA3647","article-title":"Depemokimab PK\/PD in the 52-week randomised double-blind multicentre phase III SWIFT-1 trial","volume":"64","author":"Pavord I","year":"2024","unstructured":"Pavord I, Schalkwijk S, Thorsted A, Bird N, Jacques L, Korn S. Depemokimab PK\/PD in the 52-week randomised double-blind multicentre phase III SWIFT-1 trial. Eur Respir J. 2024;64(suppl 68):OA3647.","journal-title":"Eur Respir J"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1533\/9781908818096.111"},{"key":"e_1_3_4_57_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/B978-0-12-417205-0.00002-X","volume-title":"The practice of medicinal chemistry","author":"Dougall IG","year":"2015","unstructured":"Dougall IG, Unitt J. Chapter 2 \u2013 Evaluation of the biological activity of compounds: techniques and mechanism of action studies. In: Wermuth CG, Aldous D, Raboisson P, Rognan D, editors. The practice of medicinal chemistry. 4th ed. San Diego (CA): Academic Press; 2015. p. 15\u201343.","edition":"4"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00302"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.04.020"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2678"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.05.004"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.03.004"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.23838\/pfm.2022.00072"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2019.1604745"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.12.1054"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.06.048"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-020-00910-y"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2285277"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2023-0079"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40629-022-00220-x"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-024-08790-y"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0088-2024"},{"key":"e_1_3_4_73_1","unstructured":"GlaxoSmithKline. A study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosinophilic phenotype (NIMBLE). ClinicalTrials.gov; 2021 [accessed 2025 Aug 14]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04718389."},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.10.2233"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin24.156"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15074"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-012-2663-2"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A1309"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin21.017"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.02.034"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.23249"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.02.015"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A7147"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S389865"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122312"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.3109\/03009748809102969"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2010.06.165"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2018.08.032"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-012-0108-9"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2732017"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.123892"},{"key":"e_1_3_4_92_1","first-page":"1","volume-title":"xPharm: the comprehensive pharmacology reference","author":"Sultatos L","year":"2007","unstructured":"Sultatos L. Routes of drug administration. In: Enna SJ, Bylund DB, editors. xPharm: the comprehensive pharmacology reference. New York: Elsevier; 2007. p. 1\u20133."},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12224"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-022-00361-3"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1506"}],"container-title":["Human Vaccines & Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2026.2658911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:48:27Z","timestamp":1780508907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2026.2658911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/21645515.2026.2658911"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2026.2658911","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2658911"}}